A Study of CK-2127107 in Patients With Spinal Muscular Atrophy

• Register: ClinicalTrials.gov
• Last refreshed on: 12 December 2020
• Main ID: NCT02644668
• Date of registration: 23/12/2015
• Prospective Registration: Yes
• Primary sponsor: Cytokinetics
• Public title: A Study of CK-2127107 in Patients With Spinal Muscular Atrophy
• Scientific title: A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Multiple Dose Study of CK-2127107 in Two Ascending Dose Cohorts of Patients With Spinal Muscular Atrophy
• Date of first enrolment: January 14, 2016
• Target sample size: 70
• Recruitment status: Completed
• URL: https://clinicaltrials.gov/show/NCT02644668
• Study type: Interventional
• Study design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Investigator, Outcomes Assessor).
• Phase: Phase 2

Countries of recruitment

Canada, United States

Contacts

• Name: MD, Cytokinetics
• Affiliation: Cytokinetics, Inc.

Key inclusion & exclusion criteria

Inclusion Criteria:

- Able to comprehend and willing to sign an Informed Consent Form (ICF) for patients 18
years of age and older. For patients less than 18 years of age, parent(s)/legal
guardian(s) of patients must provide written informed consent prior to participation
in the study and informed assent will be obtained from minors at least 12 years of age
when required by regulation.

- Males or females with genetically confirmed diagnosis of SMA who are Type II, III or
IV and at least 12 years of age

- Ambulatory patients, once having achieved a standing position independently, must be
able to complete at least one lap in the 6-minute walk test (at least 50 meters)
within 6 minutes without assistance.

- Non-ambulatory patients (defined as individuals who are effectively requiring a
wheelchair for all mobility needs; they may be able to stand or walk short distances,
but unable to walk 50 meters without assistance in 6 minutes). Non-ambulatory patients
must be able to tolerate an upright sitting position, with support, continuously for 3
hours

- Hammersmith (HFMS-E) score = 10 and = 54

- Contracture of the elbow flexion and knee flexion = 90 degrees

- Pre-study clinical laboratory findings within the normal range or, if outside the
normal range, deemed not clinically significant by the Investigator

- Able to swallow an oral suspension and in the opinion of the Investigator, is expected
to continue to be able to do so for the duration of the trial. Administration via a
feeding tube is not allowed.

- Forced vital capacity (FVC) > 20% predicted

- Male patients who have reached puberty must agree to do either of the following from
Screening until 10 weeks after the last dose of the investigational product unless
they have had a vasectomy and confirmed sperm count is zero:

- Abstain from sexual intercourse, OR

- If having heterosexual intercourse, must use a condom and their female partners
who are of childbearing potential must use a highly effective contraception
method*

- Female patients who have had their first period will be considered of childbearing
potential unless they are anatomically and physiologically incapable of becoming
pregnant. If of childbearing potential, the female patients must:

- Have a negative urine/serum pregnancy test at Screening AND

- Abstain from heterosexual intercourse from Screening until 10 weeks after the
last dose of investigational product OR

- If having heterosexual intercourse, must use a highly effective contraception
method* and require the male partners to use a condom from Screening until 10
weeks after the last dose of investigational product

*Highly effective contraception methods include:

- Established use of oral, injected or implanted hormonal methods of contraception

- Placement of an intrauterine device (IUD) or intrauterine system (IUS)

- Male patients must agree to refrain from sperm donation from Screening until 10 weeks
after the final study drug administration

Exclusion Criteria:

- History of significant hypersensitivity, intolerance, or allergy to any drug compound,
food, or other substance, unless approved by the Investigator

- Hospitalization within 2 months of Screening

- History of stomach or intestinal surgery or resection that would potentially alter
absorption and/or excretion of orally administered drugs (appendectomy, hernia repair,
and/or cholecystectomy will be allowed)

- A clinically significant illness within 4 weeks of Screening

- History of alcoholism or drug addiction within 2 years prior to Screening

- History of smoking more than 10 cigarettes (or equivalent amount of tobacco) per day
within 3 months prior to Screening

- Patient has used a strong CYP3A4 inhibitor within 7 days prior to first dose of study
drug or a strong CYP3A4 inducer within 14 days prior to first dose of study drug

- Any other medical condition that would interfere with performance of testing including
(but not limited to) significant joint pain or arthritis limiting mobility, and
chronic neuromuscular pain sufficient to require ongoing analgesic medication

- Participation by two people at the same time that are living in the same household

- Participation in any other investigational study drug trial in which receipt of an
investigational study drug occurred within 30 days or five half-lives of the other
investigational study drug, whichever is greater, prior to Screening

- An ALT or AST greater than 2-fold the upper limit of normal (ULN) or has total
bilirubin greater than the ULN at screening. These assessments may be repeated once at
the investigator's discretion (within the screening window)

- Currently taking nusinersen, or has taken it in the past, or plans to take it during
the course the study



Age minimum: 12 Years
Age maximum: N/A
Gender: All

Health Condition(s) or Problem(s) studied

Spinal Muscular Atrophy

Intervention(s)

Drug: Placebo

Drug: Reldesemtiv 150 mg

Drug: Reldesemtiv 450 mg

Primary Outcome(s)

Change From Baseline to Week 8 in Revised Upper Limb Module (RULM) [Time Frame: baseline and 8 weeks]

Change From Baseline to Week 8 in the 6MWT [Time Frame: baseline and 8 weeks]

Patient Global Assessment at the End of Week 8 [Time Frame: 8 weeks]

Change From Baseline to Week 8 in the Hammersmith Functional Motor Scale-Expanded (HFMS-E) [Time Frame: baseline and 8 weeks]

Change From Baseline to Week 8 in Maximum Expiratory Pressure (MEP) [Time Frame: baseline and 8 weeks]

Change From Baseline to Week 8 in the TUG Test [Time Frame: baseline and 8 weeks]

Investigator Global Assessment at the End of Week 8 [Time Frame: 8 weeks]

Change From Baseline to Week 8 in Forced Vital Capacity (FVC) [Time Frame: baseline and 8 weeks]

Muscle Strength Mega-Score at Week 8 [Time Frame: baseline and 8 weeks]

Change From Baseline to Week 8 in Maximum Inspiratory Pressure (MIP) [Time Frame: baseline and 8 weeks]

Secondary Outcome(s)

Reldesemtiv Maximum Observed Plasma Concentration (Cmax) [Time Frame: End of Week 8]

Reldesemtiv Area Under the Plasma Concentration-time Curve From 0 to 12 Hours (AUC0-12) [Time Frame: End of Week 8]

Secondary ID(s)

CY 5021

Source(s) of Monetary Support

Please refer to primary and secondary sponsors

Secondary Sponsor(s)

Astellas Pharma Global Development, Inc.

Results

• Results available: Yes
• Date Posted: 31/08/2020
• URL: https://clinicaltrials.gov/ct2/show/results/NCT02644668